Shattuck Labs SL-172154 Phase 1A/B Clinical Data 2023

Shattuck Labs presented Phase 1A/B clinical data for SL-172154 combined with Azacitidine in high-risk myelodysplastic syndrome (HR-MDS) and TP53-mutant acute myeloid leukemia (AML). The presentation, delivered on December 13, 2023, includes initial clinical outcomes and frontline dose-expansion data from the investigational combination therapy program.